Literature DB >> 21564087

Characteristics and molecular basis of celecoxib modulation on K(v)7 potassium channels.

X N Du1, X Zhang, J L Qi, H L An, J W Li, Y M Wan, Y Fu, H X Gao, Z B Gao, Y Zhan, H L Zhang.   

Abstract

BACKGROUND AND
PURPOSE: Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used for the treatment of pain and inflammation. Emerging and accumulating evidence suggests that celecoxib can affect cellular targets other than COX, such as ion channels. In this study, we characterized the effects of celecoxib on K(v)7 K(+) channels and compared its effects with the well-established K(v)7 channel opener retigabine. EXPERIMENTAL APPROACH: A perforated whole-cell patch technique was used to record K(v)7currents expressed in HEK 293 cells and M-type currents from rat superior cervical ganglion neurons. KEY
RESULTS: Celecoxib enhanced K(v)7.2-7.4, K(v)7.2/7.3 and K(v)7.3/7.5 currents but inhibited K(v)7.1 and K(v)7.1/KCNE1 currents and these effects were concentration dependent. The IC(50) value for inhibition of K(v)7.1 channels was approximately 4 µM and the EC(50) values for activation of K(v)7.2-7.4, K(v)7.2/K(v)7.3 and K(v)7.3/K(v)7.5 channels were approximately 2-5 µM. The effects of celecoxib were manifested by increasing current amplitudes, shifting the voltage-dependent activation curve in a more negative direction and slowing the deactivation of K(v)7 currents. 2,5-Dimethyl-celecoxib, a celecoxib analogue devoid of COX inhibition activity, has similar but greater effects on K(v)7currents. K(v)7.2(A235T) and K(v) 7.2(W236L) mutant channels, which have greatly attenuated responses to retigabine, showed a reversed response to celecoxib, from activation to inhibition. CONCLUSIONS AND IMPLICATIONS: These results suggest that K(v)7 channels are targets of celecoxib action and provide new mechanistic evidence for understanding the effects of celecoxib. They also provide a new approach to developing K(v)7 modulators and for studying the structure-function relationship of K(v)7 channels.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21564087      PMCID: PMC3230818          DOI: 10.1111/j.1476-5381.2011.01483.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

2.  Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.

Authors:  M C Sanguinetti; M E Curran; A Zou; J Shen; P S Spector; D L Atkinson; M T Keating
Journal:  Nature       Date:  1996-11-07       Impact factor: 49.962

3.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.

Authors:  H S Wang; Z Pan; W Shi; B S Brown; R S Wymore; I S Cohen; J E Dixon; D McKinnon
Journal:  Science       Date:  1998-12-04       Impact factor: 47.728

4.  Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

Authors:  William B White; Christine R West; Jeffrey S Borer; Philip B Gorelick; Lisa Lavange; Sharon X Pan; Ethan Weiner; Kenneth M Verburg
Journal:  Am J Cardiol       Date:  2006-11-10       Impact factor: 2.778

5.  Novel Actions of Nonsteroidal Anti-Inflammatory Drugs on Vascular Ion Channels: Accounting for Cardiovascular Side Effects and Identifying New Therapeutic Applications.

Authors:  Lioubov I Brueggemann; Bharath K Mani; Alexander R Mackie; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Cell Pharmacol       Date:  2010

6.  A retrospective review of the effect of COX-2 inhibitors on blood pressure change.

Authors:  Jeannie Cho; Catherine E Cooke; Woody Proveaux
Journal:  Am J Ther       Date:  2003 Sep-Oct       Impact factor: 2.688

7.  Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels.

Authors:  J K Hadley; M Noda; A A Selyanko; I C Wood; F C Abogadie; D A Brown
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

8.  Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.

Authors:  S Y M Yeung; V Pucovský; J D Moffatt; L Saldanha; M Schwake; S Ohya; I A Greenwood
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

9.  KCNQ/M currents in sensory neurons: significance for pain therapy.

Authors:  Gayle M Passmore; Alexander A Selyanko; Mohini Mistry; Mona Al-Qatari; Stephen J Marsh; Elizabeth A Matthews; Anthony H Dickenson; Terry A Brown; Stephen A Burbidge; Martin Main; David A Brown
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

10.  The SWISS-MODEL Repository and associated resources.

Authors:  Florian Kiefer; Konstantin Arnold; Michael Künzli; Lorenza Bordoli; Torsten Schwede
Journal:  Nucleic Acids Res       Date:  2008-10-18       Impact factor: 16.971

View more
  14 in total

1.  KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.

Authors:  Lioubov I Brueggemann; Jennifer M Haick; Samantha Neuburg; Shawn Tate; Devjit Randhawa; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-17       Impact factor: 5.464

2.  Celecoxib Ameliorates Seizure Susceptibility in Autosomal Dominant Lateral Temporal Epilepsy.

Authors:  Lin Zhou; Liang Zhou; Li-da Su; Sheng-Long Cao; Ya-Jun Xie; Na Wang; Chong-Yu Shao; Ya-Nan Wang; Jia-Huan Zhou; John K Cowell; Ying Shen
Journal:  J Neurosci       Date:  2018-02-28       Impact factor: 6.167

3.  Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58.

Authors:  F Zhang; Y Mi; J L Qi; J W Li; M Si; B C Guan; X N Du; H L An; H L Zhang
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels.

Authors:  Stefan Spyra; Anne Meisner; Michael Schaefer; Kerstin Hill
Journal:  Br J Pharmacol       Date:  2017-06-29       Impact factor: 8.739

Review 5.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Selective activation of vascular Kv 7.4/Kv 7.5 K+ channels by fasudil contributes to its vasorelaxant effect.

Authors:  Xuan Zhang; Hailong An; Junwei Li; Yuanyuan Zhang; Yang Liu; Zhanfeng Jia; Wei Zhang; Li Chu; Hailin Zhang
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

7.  The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential.

Authors:  A Boehlen; M Schwake; R Dost; A Kunert; P Fidzinski; U Heinemann; C Gebhardt
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 8.  Chemical modulation of Kv7 potassium channels.

Authors:  Matteo Borgini; Pravat Mondal; Ruiting Liu; Peter Wipf
Journal:  RSC Med Chem       Date:  2021-01-14

9.  Evidence of more ion channels inhibited by celecoxib: KV1.3 and L-type Ca(2+) channels.

Authors:  Roman V Frolov; Satpal Singh
Journal:  BMC Res Notes       Date:  2015-03-01

10.  The role of potassium channel activation in celecoxib-induced analgesic action.

Authors:  Yao Mi; Xuan Zhang; Fan Zhang; Jinlong Qi; Haixia Gao; Dongyang Huang; Li Li; Hailin Zhang; Xiaona Du
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.